Exicure And Bluejay Therapeutics Enter Into Patent License Agreement To Develop Cavrotolimod For Hepatitis; Bluejay Receive Exclusive License In Hepatitis Field To All Exicure's Relevant Patents; Paid Initial One-Time Payment; Entitled To Royalties
Portfolio Pulse from Benzinga Newsdesk
Exicure and Bluejay Therapeutics have entered into a patent license agreement for the development of Cavrotolimod for hepatitis. Bluejay receives an exclusive license to Exicure's patents in this field, with an initial payment made to Exicure and future royalties on net sales agreed upon. Exicure retains responsibility for the patents' maintenance and legal processes.
February 05, 2024 | 9:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Exicure enters a licensing agreement with Bluejay Therapeutics for hepatitis treatment development, receiving an initial payment and future royalties on net sales.
The agreement with Bluejay Therapeutics is likely to have a positive short-term impact on Exicure's stock (XCUR) due to the initial payment and the potential for future revenue through royalties. This partnership could also enhance Exicure's reputation in the biotech industry, potentially leading to increased investor confidence.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100